Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells—an in-vitro study

Head & Face Medicine

Ulrich Harréus¹  Teresa F. Brunner²  Florian A. Probst²  Matthias Troeltzsch²  Sven Becker³  Sabina Schwenk-Zieger⁴  Christian Welz⁵  Julia L. Zimmermann⁶  Gregor Morfill⁶ 

[1] Department of ENT/Head and Neck Surgery, Asklepios Hospital;Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, University Hospital, LMU;Department of Otolaryngology, Head and Neck Surgery, University Hospital, EKU;Department of Otolaryngology, Head and Neck Surgery, University Hospital, LMU;HNO München Nord;Terraplasma GmbH;

关键词: Cold atmospheric plasma;    Head and neck cancer;    Adjuvant combination therapy;   

DOI  :  10.1186/s13005-022-00322-5

来源: DOAJ

【 摘 要 】

Abstract Background The aim of the present study was to examine the cytostatic effects of cold atmospheric plasma (CAP) on different head and neck squamous carcinoma (HNSCC) cell lines either in isolation or in combination with low dose cisplatin. The effect of CAP treatment was investigated by using three different HNSCC cell lines (chemo-resistant Cal 27, chemo-sensitive FaDu and OSC 19). Materials and method Cell lines were exposed to CAP treatment for 30, 60, 90, 120 and 180 s (s). Cisplatin was added concurrently (cc) or 24 h after CAP application (cs). Cell viability, DNA damage and apoptosis was evaluated by dye exclusion, MTT, alkaline microgel electrophoresis assay and Annexin V-Fit-C/PI respectively. Results In all cell lines, 120 s of CAP exposure resulted in a significant reduction of cell viability. DNA damage significantly increased after 60 s. Combined treatment of cells with CAP and low dose cisplatin showed additive effects. A possible sensitivity to cisplatin could be restored in Cal 27 cells by CAP application. Conclusion CAP shows strong cytostatic effects in HNSCC cell lines that can be increased by concurrent cisplatin treatment, suggesting that CAP may enhance the therapeutic efficacy of low dose cisplatin.

【 授权许可】

Unknown